News

As part of the three-year deal, several collaborative studies will be conducted in tumor types such as gastroesophageal adenocarcinoma, pancreatic adenocarcinoma and hepatocellular carcinoma. Under the deal, the

This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment

The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the

In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort)

The availability of Karbinal ER provides physicians with a new, effective and easy to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic

As part of the deal, CMC will develop a CHEF1 production cell line and process for manufacture of MVI’s monoclonal antibody, targeting circumsporozoite protein (CSP), for use by

SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand. The agreement includes upfront and milestone

Earlier in January, the company entered into a world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications. So far, the company has secured $20.5m of

The trial met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells in a pre-defined proportion of people